domingo, 30 de octubre de 2016

Prevention and Screening in Hereditary Breast and Ovarian Cancer. - PubMed - NCBI

Prevention and Screening in Hereditary Breast and Ovarian Cancer. - PubMed - NCBI



 2016 Oct 15;30(10). pii: 219285.

Prevention and Screening in Hereditary Breast and Ovarian Cancer.

Abstract

In recent years, we have learned a great deal about pathogenic mutations that increase the risk of breast and ovarian cancer, particularly mutations in the BRCA1 and BRCA2 genes. Here we review current guidelines on breast and ovarian cancer screening, prophylactic surgery, and other risk-reduction strategies in patients with these mutations, and we detail the data that drive these recommendations. We also discuss guidelines on screening and management for other cancers associated with BRCA1 and BRCA2, such as male breast cancer, pancreatic cancer, and prostate cancer. Discussions about genetic testing have become more complex with the advent of panel testing, which often allows for testing of a more comprehensive panel of genes than traditional BRCA1 and BRCA2 testing, but which is also associated with a higher likelihood of obtaining results with less clear data to inform management. It is difficult to come to a consensus on how best to address the varied and potentially challenging situations that may arise from genetic testing. The complexity inherent in managing these cases makes a multidisciplinary team-including medical oncologists, surgical oncologists, genetic counselors, reproductive endocrinologists, and medical ethicists-critical to optimization of care.

PMID:
 
27753056

[PubMed - in process] 
Free full text

No hay comentarios:

Publicar un comentario